4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,821.50 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $10.90, for a total value of $17,821.50. Following the transaction, the insider directly owned 3,594 shares of the company’s stock, valued at approximately $39,174.60. This represents a 31.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Monday, November 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.59, for a total value of $17,314.65.
• On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $32,136.00.
• On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.17, for a total value of $16,627.95.
• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.00, for a total transaction of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $8.00, for a total transaction of $19,256.00.

4D Molecular Therapeutics Stock Down 0.1%

Shares of FDMT traded down $0.01 during mid-day trading on Friday, reaching $8.68. 4,815,801 shares of the company’s stock were exchanged, compared to its average volume of 883,375. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.23 and a 52-week high of $12.34. The company has a market cap of $495.93 million, a price-to-earnings ratio of -2.31 and a beta of 2.96. The company has a 50-day simple moving average of $10.68 and a two-hundred day simple moving average of $7.47.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.01. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. As a group, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on FDMT shares. Leerink Partners reiterated an “outperform” rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Barclays decreased their price objective on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Finally, Royal Bank Of Canada upped their target price on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, November 11th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.70.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of FDMT. Acadian Asset Management LLC raised its holdings in 4D Molecular Therapeutics by 1,103.4% in the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock valued at $1,290,000 after buying an additional 367,317 shares during the period. Invesco Ltd. grew its holdings in 4D Molecular Therapeutics by 318.3% during the 1st quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock valued at $380,000 after purchasing an additional 89,611 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in 4D Molecular Therapeutics during the 1st quarter valued at $63,000. Nuveen LLC acquired a new position in 4D Molecular Therapeutics in the 1st quarter worth $486,000. Finally, Kera Capital Partners Inc. acquired a new position in 4D Molecular Therapeutics in the 2nd quarter worth $89,000. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.